根治性子宫切除术与II期子宫内膜癌生存获益无关
基于美国国家癌症数据库2004至2015年7552例II期子宫内膜癌接受子宫切除及区域淋巴结手术的患者,根治性子宫切除术(RH)占10.5%。RH组住院时间更长且90天死亡率更高,总生存与全子宫切除术(TH)组无差异(5年生存率77.4%对76.9%,p=0.62)。多因素校正后RH与生存无关联(HR 1.01,95%CI 0.85-1.21)。
要点
- II期子宫内膜癌中根治性子宫切除术率为10.5%。
- RH组住院时间更长(中位3天对2天,p<0.001),90天死亡率更高(1.6%对0.8%,p=0.05)。
- RH与全子宫切除术总生存无差异(p=0.62),校正后HR 1.01(95%CI 0.85-1.21)。
核心结论
- 在II期子宫内膜癌患者队列中,根治性子宫切除术与生存获益无关。
研究设计与样本
- 基于美国国家癌症数据库2004至2015年诊断的II期子宫内膜癌患者,接受子宫切除及区域淋巴结手术,纳入7552例,比较根治性或改良根治性子宫切除术(RH)与全子宫切除术(TH)。
主要发现
- RH率为10.5%。
- RH组住院时间中位3天,TH组2天(p<0.001)。
- RH组90天死亡率为1.6%,TH组为0.8%(p=0.05)。
- RH组与TH组总生存无差异(p=0.62),5年生存率分别为77.4%和76.9%。
- 校正年龄、种族、保险、合并症、肿瘤大小、组织学、淋巴结清扫及辅助治疗等因素后,RH与生存无关联(HR 1.01,95%CI 0.85-1.21)。
临床怎么用
- 对于II期子宫内膜癌,根治性子宫切除术未显示生存优势,且住院时间更长、90天死亡率更高,临床决策需权衡利弊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the role of radical hysterectomy in the management of patients with stage II endometrial carcinoma. MATERIALS: Patients diagnosed between 2004 and 2015, with stage II (based on the revised FIGO staging) endometrial carcinoma who had hysterectomy and regional lymph node surgery were identified in the National Cancer Database. Those who had radical or modified radical (RH), or total hysterectomy (TH) were selected. Overall survival (OS) was assessed with Kaplan-Meier curves and compared with the log-rank test. A Cox model was constructed to evaluate survival after controlling for confounders. RESULTS: A total of 7552 patients who met the inclusion criteria were identified. Rate of RH was 10.5%. Those who underwent RH had longer hospital stay (median 3 vs 2 days, p < 0.001) and a higher 90-day (1.6% vs 0.8%, p = 0.05) mortality. There was no difference in OS between patients who had RH (n = 712) and SH (n = 5955) (p = 0.62); 5-year survival rates were 77.4% and 76.9%, respectively. After controlling for patient age (<65, ≥65 years), race (white, black, other/unknown), insurance status, presence of comorbidities, tumor size (<5, ≥5 cm, unknown), histology (endometrioid, non-endometrioid), performance of adequate lymphadenectomy, and receipt of adjuvant chemotherapy and radiation therapy, performance of radical hysterectomy was not associated with better survival (HR: 1.01, 95% CI: 0.85, 1.21). CONCLUSIONS: Radical hysterectomy was not associated with a survival benefit in a cohort of patients with stage II endometrial carcinoma.
引用
- Nasioudis D, Sakamuri S, Ko EM, et al. Radical hysterectomy is not associated with a survival benefit for patients with stage II endometrial carcinoma. Gynecol Oncol. 2020. PMID: 32089334. doi:10.1016/j.ygyno.2020.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。